Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Hair loss is a common side effect of hormone treatments for cancer.

In this case report, the authors describe a partial androgen insensitivity syndrome patient with a novel AR gene mutation, highlighting challenges in gender assignment decisions for infants with partial AIS.

This review discusses various diagnostic and treatment strategies for canine prostate diseases, including pharmacological options and advanced procedures, but reports no new clinical results.

This review explores the hormonal regulation of hair growth and changes with season, age, and sexual development, and calls for improved treatments for hair disorders.

This paper discusses the role of steroid sulfatase in hormone-dependent tumors and highlights the development of potent inhibitors, noting the commencement of a phase I trial for one inhibitor in postmenopausal breast cancer patients.

This review discusses the role of DHEA in intracrinology, highlighting its impact on breast and prostate cancer treatment and potential as a menopause therapy, but reports no new research findings.

Male hormones affect COVID-19 severity and certain drugs targeting these hormones could help reduce the risk.

This study explains finasteride's high potency and specificity as a mechanism-based inhibitor for treating benign prostatic hyperplasia by detailing its interaction with human type 2 steroid 5α-reductase.

This article discusses the structure of the human type II 5 alpha-reductase gene and reports no new experimental results.

Dihydrotestosterone gel improved well-being and sexual function in older men without negatively affecting prostate health.

This study concluded that daily treatment with 1 mg finasteride did not affect spermatogenesis or semen production in young men and had small, reversible effects on prostate volume and serum PSA.

In this study, older men using 5α-reductase inhibitors for prostatic enlargement did not show increased risk of suicide, but had elevated risks of self-harm and depression.

Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.

This study found that the progestins norgestimate and dienogest may help treat clinical hyperandrogeny in women by inhibiting skin 5 alpha-reductase activity with minimal androgenic potential.

This article discusses the potential effects of exogenous testosterone, highlighting that its impact on prostate cancer progression, cardiovascular health, and behavior remains uncertain and needs further investigation.

This article reviews the reported sexual and psychological side effects of 5-alpha reductase inhibitors for benign prostatic hyperplasia, emphasizing the need for further clinical studies.

This study found that SRD5a-3 is a highly efficient enzyme for converting hormones into androgens, with dutasteride being a much more potent inhibitor of SRD5a-3 than SRD5a-2.

This study reported that certain newly synthesized steroidal derivatives showed stronger inhibitory activity against the 5α-reductase enzyme than finasteride in hamsters, suggesting their potential as enzyme inhibitors.

This study found that finasteride significantly alters urinary steroid profiles, complicating the detection of steroid abuse in doping-control analysis by potentially causing false-negative results.

This study found that 4-MA is a potent inhibitor of testosterone 5α-reductase in human tissues, promising potential for treating androgen-dependent skin conditions like male pattern baldness.

This review discusses the potential role of androgen receptor CAG repeat polymorphism testing in hypogonadism management for both sexes, but its clinical utility remains unclear and requires further investigation.

This review provides an overview of the risks and side effects associated with common medications used to treat benign prostatic hyperplasia, highlighting the importance for clinicians and patients to discuss these aspects for informed decision-making.

This review discusses the structure and function of steroid nuclear receptors, particularly focusing on androgen receptor dysregulation in prostate cancer and androgen insensitivity syndromes, without reporting new experimental results.

Testosterone therapy aims to treat hormone deficiencies and various conditions safely and effectively, but requires careful patient monitoring due to potential side effects.

This review discusses persistent sexual and nonsexual adverse effects of the 5α-reductase inhibitor finasteride in younger men, including erectile dysfunction, low libido, and depression. It reports no new clinical results but emphasizes further research is needed.

This review discusses the pathophysiology of delayed ejaculation, highlighting the role of various biogenic and psychogenic factors, but reports no new clinical findings.

This study reports that five new progesterone derivatives demonstrated inhibitory activity against the 5α-reductase enzyme and binding affinity for the androgen receptor in an in vitro hamster model.

In this study of elderly patients at an Indian medical center, researchers found that xerosis was the most common physiological skin change and pruritus was the most frequent complaint.

This study constructed a model to predict finasteride's inhibitory activity on 5α-reductase type 2 and calculated that a 1 μM plasma concentration, after 50 mg administration, matches prostate inhibition levels.

This study found that Lespedeza cuneata aqueous extract reduced serum dihydrotestosterone levels and 5α-reductase mRNA expression in testosterone-induced prostatic hyperplasia in rats, suggesting potential as a treatment for prostatic hyperplasia.